We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Current status of biosimilars in Turkey: A survey among medical oncologists.
- Authors
Gürler, Fatih; Kasım, Demet Döndü; Kurt İnci, Bediz; Sütçüoğlu, Osman; Ünsal, Oktay; Aslan, Volkan; Tahtacı, Gözde; Özdemir, Nuriye; Üner, Aytuğ; Günel, Nazan; Özet, Ahmet; Yazıcı, Ozan
- Abstract
Introduction: To evaluate biosimilar understanding and preference trends of medical oncologists in Turkey. Methods: A survey consisting of 24 multiple-choice questions with checkbox answers was conducted among medical oncologists. The questionnaire was divided into five parts to some intentions: demographic characteristics, general knowledge about biosimilars, knowledge about local approval and reimbursement issues, individual preference trends, and ranking the knowledge of their own. All answers were analyzed as whole cohort, specialists and fellows. Results: Fellows (n = 47) consisted 42%, and academic clinicians (n = 37) consisted 35% of the participants. In the whole cohort, the overall rate of correct answers was 55.1% in the general knowledge about the biosimilars part, and 26.7% in the local approval and reimbursement issues part. At all, 57.7% of the participants declared that they object to switch from a reference product to a biosimilar product. The rate of those who defined themselves as extremely knowledgeable decreased from 8.1% to 2.7% in the whole cohort at the end of the survey. Conclusion: The need for more accurate and clarified local regulations and education emerging in the biotechnology era must be met.
- Subjects
TURKEY; DRUG approval; BIOLOGICAL products; BIOSIMILARS; SURVEYS; COMMERCIAL product evaluation; QUESTIONNAIRES; ONCOLOGISTS; BIOTECHNOLOGY
- Publication
Journal of Oncology Pharmacy Practice, 2022, Vol 28, Issue 7, p1516
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/10781552211031643